A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
Original languageEnglish
JournalGynecologic Oncology
Issue number2
Pages (from-to)308-13
Number of pages6
Publication statusPublished - 2011

ID: 40150550